Mycoplasma genitalium retrospective audit of Northern Territory isolates from 2022
DOI:
https://doi.org/10.33321/cdi.2024.48.43Abstract
The Northern Territory (NT) has the highest rates of sexually transmitted infections (STI) in Australia; however, the local prevalence of Mycoplasma genitalium (M. genitalium) has not been previously determined. This study was designed to review M. genitalium detection, to determine the regional NT prevalence and macrolide resistance rates. In our study the NT background prevalence of M. genitalium is 13%, with the highest detection rates occurring in central Australia and in correctional facility inmates. Symptomatic patients attending sexual health clinics have a positivity rate of 12%, but very high macrolide resistance. The decision to screen for M. genitalium should be based on several factors, including the prevalence of the infection in the local population; the availability of effective treatments; and the potential benefits and risks of detection and therapy.
Downloads
References
Northern Territory Government Department of Health (NT Health). NT Guidelines for the Management of Sexually Transmitted Infections in the Primary Health Care setting. 5th Edition 2019. Darwin: NT Health; April 2019. [Accessed in August 2023.] Available from: https://digitallibrary.health.nt.gov.au/prodjspui/bitstream/10137/1298/3/Updated%20NT%20STI%20Guidelines%20April%202019.pdf.
Australian Government Department of Health and Aged Care. Mycoplasma genitalium – Laboratory case definition. [Webpage.] Canberra: Australian Government Department of Health and Aged Care, Public Health Laboratory Network; 17 October 2019. [Accessed on 26 May 2023.] Available from: https://www.health.gov.au/resources/publications/mycoplasma-genitalium-laboratory-case-definition.
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI management guidelines for use in primary care. Mycoplasma genitalium. [Webpage.] Sydney: ASHM; December 2021. [Accessed on 26 May 2023.] Available from: https://sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium/.
Frenzer C, Egli-Gany D, Vallely LM, Vallely AJ, Low N. Adverse pregnancy and perinatal outcomes associated with Mycoplasma genitalium: systematic review and meta-analysis. Sex Transm Infect. 2022;98(3):222–7. doi: https://doi.org/10.1136/sextrans-2021-055352.
Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer GR et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis. Sex Transm Infect. 2018;94(4):255–62. doi: https://doi.org/10.1136/sextrans-2017-053384.
Trevis T, Gossé M, Santarossa N, Tabrizi S, Russell D, McBride WJ. Mycoplasma genitalium in the Far North Queensland backpacker population: an observational study of prevalence and azithromycin resistance. PLoS One. 2018;13(8):e0202428. doi: https://doi.org/10.1371/journal.pone.0202428.
Latimer RL, Shilling HS, Vodstrcil LA, Machalek DA, Fairley CK, Chow EPF et al. Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a systematic review and meta-analysis. Sex Transm Infect. 2020;96(8):563–70. doi: https://doi.org/10.1136/sextrans-2019-054310.
Durukan D, Read TRH, Murray G, Doyle M, Chow EPF, Vodstrcil LA et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis. 2020;71(6):1461–8. doi: https://doi.org/10.1093/cid/ciz1031.
Machalek DA, Yusha T, Shilling H, Jensen JS, Unemo M, Murray G et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20(11):1302–14. doi: https://doi.org/10.1016/S1473-3099(20)30154-7.
Spencer SJ. Striving for balance between participation and protection in research involving prison populations. Aust N Z J Psychiatry. 2017;51(10):974–6. doi: https://doi.org/10.1177/0004867417714880.
Manhart LE, Leipertz G, Soge OO, Jordan SJ, McNeil C, Pathela P et al. Mycoplasma genitalium in the US (MyGeniUS): surveillance data from sexual health clinics in four US regions. Clin Infect Dis. 2023;ciad405. doi: https://doi.org/10.1093/cid/ciad405.
Tickner JA, Bradshaw CS, Murray GL, Whiley DM, Sweeney EL. Novel probe-based melting curve assays for the characterization of fluoroquinolone resistance in Mycoplasma genitalium. J Antimicrob Chemother. 2022;77(6):1592–9. doi: https://doi.org/10.1093/jac/dkac097.
Wood GE, Bradshaw CS, Manhart LE. Update in epidemiology and management of Mycoplasma genitalium infections. Infect Dis Clin North Am. 2023;37(2):311–3. doi: https://doi.org/10.1016/j.idc.2023.02.009.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
